Not an 'excellent outcome' for Athersys stock as stem cell therapy misses endpoint in Japanese trial

Not an 'excellent outcome' for Athersys stock as stem cell therapy misses endpoint in Japanese trial

Source: 
Fierce Biotech
snippet: 


Results from a trial by Athersys’ Japanese partner Healios showed that patients with ischemic stroke who received a single dose of the MultiStem therapy did not show a statistically significant achievement of the primary endpoint of an “excellent outcome” at 90 days.